BACKGROUND: Amikacin and kanamycin are frequently used in the treatment of multidrug-resistant TB. The current commercially available immunoassay is unable to analyze kanamycin and trough levels of amikacin. The objective was therefore to develop a LC-MS/MS method for the quantification of amikacin and kanamycin in human serum. MATERIALS & METHODS: Using apramycin as internal standard, selectivity, accuracy, precision, recovery, matrix effects and stability were evaluated. RESULTS: The presented LC-MS/MS method meets the recommendations of the US FDA with a low LLOQ of 250 ng/ml for amikacin and 100 ng/ml for kanamycin. No statistical significant difference was found between the LC-MS/MS method and the immunoassay of amikacin (Architect(®) assay, p = 0.501). CONCLUSION: The low LLOQ of amikacin and the ability to analyze kanamycin makes the LC-MS/MS method the preferred method for analyzing these aminoglycosides.
BACKGROUND:Amikacin and kanamycin are frequently used in the treatment of multidrug-resistant TB. The current commercially available immunoassay is unable to analyze kanamycin and trough levels of amikacin. The objective was therefore to develop a LC-MS/MS method for the quantification of amikacin and kanamycin in human serum. MATERIALS & METHODS: Using apramycin as internal standard, selectivity, accuracy, precision, recovery, matrix effects and stability were evaluated. RESULTS: The presented LC-MS/MS method meets the recommendations of the US FDA with a low LLOQ of 250 ng/ml for amikacin and 100 ng/ml for kanamycin. No statistical significant difference was found between the LC-MS/MS method and the immunoassay of amikacin (Architect(®) assay, p = 0.501). CONCLUSION: The low LLOQ of amikacin and the ability to analyze kanamycin makes the LC-MS/MS method the preferred method for analyzing these aminoglycosides.
Authors: J A Dijkstra; T van der Laan; O W Akkerman; M S Bolhuis; W C M de Lange; J G W Kosterink; T S van der Werf; J W C Alffenaar; D van Soolingen Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: R van Altena; J A Dijkstra; M E van der Meer; J F Borjas Howard; J G W Kosterink; D van Soolingen; T S van der Werf; J W C Alffenaar Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez Journal: Antimicrob Agents Chemother Date: 2021-03-08 Impact factor: 5.191
Authors: A P Topolyan; M A Belyaeva; E E Bykov; P V Coodan; E A Rogozhin; D A Strizhevskaya; O M Ivanova; A V Ustinov; I V Mikhura; I A Prokhorenko; V A Korshun; A A Formanovsky Journal: Acta Naturae Date: 2016 Jul-Sep Impact factor: 1.845